Original Investigation | Pediatrics

Patent Ductus Arteriosus and Bronchopulmonary Dysplasia–Associated Pulmonary Hypertension
A Bayesian Meta-Analysis

Eduardo Villamor, MD, PhD; Elke van Westering-Kroon, MD; Gema E. Gonzalez-Luis, MD, PhD; František Bartoš, MSc; Steven H. Abman, MD; Maurice J. Huizing, MSc

Abstract

**IMPORTANCE** Bronchopulmonary dysplasia (BPD) is often associated with pulmonary vascular disease and secondary pulmonary hypertension (PH). The pathogenesis of BPD-associated PH (BPD-PH) is complex and involves prenatal and postnatal factors that disrupt pulmonary vascular development, and patent ductus arteriosus (PDA) is a factor potentially associated with risk of BPD-PH that has been identified in very recent studies.

**OBJECTIVE** To explore the association of PDA with BPD-PH using a bayesian model-averaged (BMA) meta-analysis of studies.

**DATA SOURCES** PubMed and Embase were searched up to April 2023. Key search terms included BPD and PH.

**STUDY SELECTION** Studies examining infants with gestational age 32 weeks or less and reporting data on PDA and risk of BPD-PH.

**DATA EXTRACTION AND SYNTHESIS** This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the Meta-Analysis of Observational Studies in Epidemiology reporting guidelines. Two independent reviewers extracted data, with a third reviewer checking for accuracy and completeness. Data pooling and effect size calculations were performed by BMA.

**MAIN OUTCOMES AND MEASURES** The primary outcome was BPD-PH. BMA was used to calculate Bayes factors (BFs). The BF$_{10}$ is the ratio of the probability of the data under the alternative hypothesis (H$_{a}$, association of PDA with BPD-HP) over the probability of the data under the null hypothesis (H$_{0}$).

**RESULTS** A total of 32 studies (8513 infants) were included. BMA showed that the evidence in favor of H$_{1}$ was weak for any PDA (BF$_{10} = 2.90$; 10 studies), moderate for hemodynamically significant PDA (BF$_{10} = 3.77$; 3 studies), and extreme for surgically ligated or catheter-occluded PDA (BF$_{10} = 294.9$; 16 studies). In contrast, the evidence in favor of H$_{0}$ was weak for medically treated PDA (BF$_{10} = 0.55$; 6 studies). In addition, BMA found strong evidence in favor of H$_{1}$ when prolonged exposure to PDA was analyzed as a dichotomous variable (BF$_{10} = 11.80$; 6 studies) and extreme evidence (BF$_{10} = 113.60$; 3 studies) when PDA exposure time was analyzed as a continuous variable.

**CONCLUSIONS AND RELEVANCE** In this bayesian meta-analysis, the data suggest that prolonged exposure to PDA might be associated with increased risk of pulmonary vascular disease in extremely preterm infants. This highlights the need to monitor for PH in high-risk preterm infants with prolonged exposure to PDA.

Key Points

**Question** Is patent ductus arteriosus (PDA) associated with a higher risk of developing bronchopulmonary dysplasia–associated pulmonary hypertension (BPD-PH) among very and extremely preterm infants?

**Findings** In this meta-analysis of 32 studies with 8513 infants, the bayesian model-averaged meta-analysis found associations of BPD-PH with both PDA requiring surgery and prolonged PDA.

**Meaning** These findings suggest that sustained patency of a hemodynamically significant ductal shunt may be a key contributor to pulmonary vascular disease in very and extremely preterm infants and highlight the need to monitor for PH in high-risk preterm infants and to incorporate PH risk into clinical decisions regarding PDA management.

Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.
prolonged exposure to PDA and to incorporate PH risk into clinical decisions regarding PDA management.

Introduction

Bronchopulmonary dysplasia (BPD) is one of the most common complications of very and extremely preterm birth (ie, gestational age <32 weeks) and is an important contributor to pulmonary and nonpulmonary morbidity and mortality. BPD is often associated with pulmonary vascular disease and secondary pulmonary hypertension (PH). BPD-associated pulmonary hypertension (BPD-PH) is characterized by arrested vascular growth and abnormal remodeling of the pulmonary vasculature, resulting in high vascular tone and abnormal reactivity, which may lead to increased pulmonary vascular resistance and right heart failure. The pathogenesis of BPD-PH is multifactorial and involves maternal, placental, fetal, and postnatal factors that disrupt fetal and neonatal growth and development of the pulmonary vascular bed. BPD-PH is estimated to be present in 25% of infants with moderate-to-severe BPD, and its presence is associated with worse respiratory outcomes and higher hospital readmission and mortality rates.

Although there is no consensus on the diagnostic criteria for BPD-PH, a growing number of observational studies have been published comparing infants with PH, as assessed by echocardiography, with infants having BPD without PH. This has allowed the identification of several prenatal and postnatal factors associated with BPD-PH. Among these factors are lower gestational age (GA), being small for GA, hypertensive disorders of pregnancy, oligohydramnios, sepsis, higher mechanical ventilation requirements, or BPD severity.

Preclinical studies have shown that hemodynamic stress impairs pulmonary vascular function, structure, and growth in animal models of perinatal PH, but the impact of a patent ductus arteriosus (PDA) on late clinical outcomes after preterm birth remains uncertain. The presence of or prolonged exposure to a hemodynamically significant PDA (hsPDA) has been suggested as a potential risk factor for developing BPD-PH in some recent cohorts. However, the potential contribution of PDA or its association with the risk of sustained or late PH in infants with established BPD has not been analyzed in the various meta-analyses published to date.

Our objective for the current study was to conduct a systematic review and meta-analysis of the association of PDA with BPD-PH. Instead of the more commonly used frequentist statistics, we used a bayesian approach for the meta-analysis. In contrast to frequentist null hypothesis (H₀) significance testing, which focuses exclusively on H₀, Bayesian hypothesis testing aims to quantify the relative plausibility of the alternative hypothesis (H₁) and H₀. Quantification of evidence on a continuous scale allows for more nuanced conclusions than do all-or-none (significant vs nonsignificant) conclusions. The bayesian approach may provide a wider, and arguably more informative, set of interpretations than that typically provided by a frequentist analysis.

Methods

The method for this study was based on our recently published experience on performing meta-analyses to study the associations of antenatal and perinatal exposures with outcomes of prematurity. Because this meta-analysis did not involve animal subjects or personally identifiable information on human participants, ethics review board approval and patient consent were not required, in accordance with Dutch law regarding human medical scientific research, which is enforced by the Central Committee on Research Involving Human Subjects. The study was...
performed and reported according to Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting
guidelines. The population, exposure, comparison, and outcome question was, do very and
extremely preterm infants (population) exposed to PDA (exposure) have a higher risk of developing
BPD-PH (outcome) than preterm infants with no history of exposure (comparison)?

Sources and Search Strategy
A comprehensive literature search was undertaken using the PubMed, EMBASE, and Web of Science
databases. The literature search was updated up to February 2023. The search strategy is detailed
in the eAppendix in Supplement 1. Studies were included if they examined very and extremely
preterm (GA <32 weeks) or very low birth weight (<1500 g) infants and reported primary data that
could be used to measure the association of exposure to PDA with the development of BPD-PH.

Data Extraction, Definitions, and Quality Assessment
Two reviewers (E.V. and E.v.W.-K.) extracted data from relevant studies, and another reviewer
(M.J.H.) checked data extraction for accuracy and completeness. Discrepancies were resolved by
consulting the primary report. The outcome considered in meta-analysis was BPD-PH, defined by
any echocardiographic criteria as long as the evaluation was performed at a postnatal age greater
than 4 weeks. The exposure to PDA was divided into 6 groups on the basis of the categories provided
in the different studies: (1) any PDA (any ductal shunt detected by echocardiography); (2) hsPDA; (3)
medically treated PDA; (4) surgically ligated or catheter-occluded PDA; (5) medically treated and/or
surgically ligated or catheter-occluded PDA; and (6) prolonged PDA (exposure to PDA beyond 4
weeks postpartum or 36 weeks postmenstrual age). When a study reported different periods of
exposure to PDA, the longest period was selected. In addition to these 6 PDA groups, PDA exposure
time was collected as a continuous variable.

Methodological quality was assessed using the Newcastle-Ottawa Scale for cohort or case-
control studies. Newcastle-Ottawa Scale scores of 7 or higher were considered high-quality studies
(low risk of bias), and scores of 5 to 6 denoted moderate quality (moderate risk of bias).

Statistical Analysis
The effect size of dichotomous variables (PDA exposure) was expressed as log odds ratio (OR), and
the effect size of continuous variables (time of exposure to PDA) was expressed using the Hedges g
value. Values of log OR or Hedges g and the corresponding SEs of each individual study were
computed using Comprehensive Meta-Analysis statistical software version 4.0 (Biostat). The results
were further pooled and analyzed by using bayesian model-averaged (BMA) meta-analysis. We
performed the BMA in JASP version 0.17.3 (JASP Team 2023), which uses the metaBMA R
package. BMA uses Bayes factors (BFs) and bayesian model averaging to evaluate the likelihood
of the data under the combination of models assuming the presence vs the absence of the meta-
analytic effect and heterogeneity. The BF_{10} is the ratio of the probability of the data under H_{1} over
the probability of the data under H_{0} and was interpreted using the evidence categories suggested
by Lee et al. The evidence in favor of H_{1} (BF_{10} >1) was categorized as weak or inconclusive (BF_{10} 1 to
<3), moderate (BF_{10} 3 to <10), strong (BF_{10} 10 to <30), very strong (BF_{10} 30 to <100), and extreme
(BF_{10} >100). The evidence in favor of H_{0} (BF_{10} <1) was categorized as weak or inconclusive (BF_{10} 1/3
to <1), moderate (BF_{10} 1/10 to <1/3), strong (BF_{10} 1/30 to <1/10), very strong (BF_{10} 1/100 to <1/30), and
extreme (BF_{10} <1/100). The BF_{r} is the ratio of the probability of the data under the random-effects
model over the probability of the data under the fixed-effect model. The categories of strength of the
evidence in favor of the random effects or the fixed effect were similar to those described already
for BF_{10}. We used the empirical prior distributions based on the Cochrane Database of Systematics
Reviews transformed to log OR; log OR = - t (μ = 0, σ = 0.78, ν = 5), and t - inverse γ (k = 1.71,
θ = 0.73). We used robust bayesian meta-analysis to assess the robustness of the results to the
potential presence of publication bias.
Results

Description of Studies and Quality Assessment
The PRISMA flow diagram of the search process is shown in eFigure 1 in Supplement 1. Of 186 potentially relevant studies, 32 studies were included.\textsuperscript{10,11,25-54} These studies included 8513 infants. Characteristics of the studies are summarized in eTable 1 in Supplement 1. Risk of bias assessment according to the Newcastle-Ottawa Scale is depicted in eTable 1 in Supplement 1. All studies received a score of at least 7 points, indicating a low risk of bias. The criteria used in the various studies for the diagnosis of BPD-PH are summarized in eTable 2 in Supplement 1.

BMA Meta-Analysis
Figure 1 and the Table summarize the results of the BMA. Detailed data on heterogeneity are presented in eTable 3 in Supplement 1, and robust bayesian meta-analysis data on publication bias are shown in eTable 4 in Supplement 1. Ten studies reported on any PDA.\textsuperscript{10,30,31,40,45,47,51,52,54} and BMA showed that the evidence in favor of H\textsubscript{1} (ie, the association between BPD-PH and PDA) was weak or inconclusive (BF\textsubscript{10} = 2.90) (Figure 2). Three studies reported on hspDA,\textsuperscript{10,49,52} and BMA showed moderate evidence in favor of H\textsubscript{1} (BF\textsubscript{10} = 3.77). Regarding PDA treatment, BMA showed extreme evidence (BF\textsubscript{10} = 294.9; 16 studies)\textsuperscript{11,25,26,28,31-33,38,42,44,45,48-50,53,54} in favor of the association between BPD-PH and surgically ligated or catheter-occluded PDA (Figure 3). In contrast, BMA showed weak or inconclusive evidence in favor of H\textsubscript{2} for the associations between BPD-PH and medically treated PDA (BF\textsubscript{10} = 0.55; 6 studies).\textsuperscript{10,25,32,36,38,44} or medically treated and/or ligated or occluded PDA (BF\textsubscript{10} = 0.90; 8 studies)\textsuperscript{27,29,32,34,39,41,43,44} (eFigure 2 in Supplement 1). Infants with BPD-PH were exposed to PDA for a pooled mean (SD) of 10.3 (2.7) days (3 studies)\textsuperscript{10,11,42} longer than were infants without BPD-PH. BMA showed strong evidence in favor of H\textsubscript{1} when prolonged exposure to PDA was analyzed as a dichotomous variable (BF\textsubscript{10} = 11.80; 6 studies)\textsuperscript{10,11,46,50,53,54} and extreme evidence (BF\textsubscript{10} = 113.60; 3 studies)\textsuperscript{10,11,42} when PDA exposure time was analyzed as a continuous variable (Figure 4). Two studies\textsuperscript{10,49} reported effect sizes after adjustment for various covariates. The adjusted and unadjusted effect sizes are shown in eTable 5 in Supplement 1. Robust bayesian
<table>
<thead>
<tr>
<th>Meta-analysis</th>
<th>K*</th>
<th>Presence of BPD-PH, No. of infants</th>
<th>Log OR (SD) [95% CrI]</th>
<th>BF&lt;sub&gt;10&lt;/sub&gt;</th>
<th>Level of evidence in favor of H&lt;sub&gt;1&lt;/sub&gt;, H&lt;sub&gt;0&lt;/sub&gt;</th>
<th>P value&lt;sup&gt;c&lt;/sup&gt;</th>
<th>BF&lt;sub&gt;rf&lt;/sub&gt;</th>
<th>Level of evidence in favor of Random effects</th>
<th>Fixed effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any PDA</td>
<td>10</td>
<td>Yes 387, No 1658</td>
<td>0.41 (0.17) [0.03 to 0.72]</td>
<td>2.90</td>
<td>Weak NA</td>
<td>.02</td>
<td>2.20</td>
<td>Weak NA</td>
<td></td>
</tr>
<tr>
<td>Hemodynamically meaningful PDA</td>
<td>3</td>
<td>Yes 200, No 796</td>
<td>0.74 (0.37) [-0.10 to 1.41]</td>
<td>3.77</td>
<td>Moderate NA</td>
<td>.02</td>
<td>6.03</td>
<td>Moderate NA</td>
<td></td>
</tr>
<tr>
<td>Medically treated PDA</td>
<td>6</td>
<td>Yes 187, No 1176</td>
<td>0.25 (0.26) [-0.27 to 0.75]</td>
<td>0.55</td>
<td>NA Weak</td>
<td>.40</td>
<td>2.19</td>
<td>Weak NA</td>
<td></td>
</tr>
<tr>
<td>Surgically ligated or catheter-occluded PDA</td>
<td>16</td>
<td>Yes 972, No 4413</td>
<td>0.84 (0.20) [0.44 to 1.23]</td>
<td>294.9</td>
<td>Extreme NA</td>
<td>&lt;.001</td>
<td>&gt;10&lt;sup&gt;6&lt;/sup&gt;</td>
<td>Extreme NA</td>
<td></td>
</tr>
<tr>
<td>Medically treated and/or surgically ligated or catheter-occluded PDA</td>
<td>8</td>
<td>Yes 234, No 787</td>
<td>0.30 (0.21) [-0.11 to 0.69]</td>
<td>0.86</td>
<td>NA Weak</td>
<td>.11</td>
<td>0.82</td>
<td>NA Weak</td>
<td></td>
</tr>
<tr>
<td>Prolonged PDA</td>
<td>6</td>
<td>Yes 288, No 810</td>
<td>1.67 (0.65) [0.23 to 2.80]</td>
<td>11.80</td>
<td>Strong NA</td>
<td>&lt;.001</td>
<td>1872.5</td>
<td>Extreme NA</td>
<td></td>
</tr>
<tr>
<td>Time of exposure to PDA</td>
<td>3</td>
<td>Yes 183, No 931</td>
<td>1.06 (0.14) [0.74 to 1.30]&lt;sup&gt;+&lt;/sup&gt;</td>
<td>113.6</td>
<td>Extreme NA</td>
<td>&lt;.001</td>
<td>0.54</td>
<td>NA Weak</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BPD-PH, bronchopulmonary dysplasia–associated pulmonary hypertension; CrI, credible interval; NA, not applicable; OR, odds ratio; PDA, patent ductus arteriosus.

<sup>a</sup> K denotes the number of studies included in the analysis.

<sup>b</sup> Bayes factor (BF<sub>10</sub>) denotes the ratio of the probability of the data under the alternative hypothesis (H<sub>1</sub>: association of PDA with BPD-HP) over the probability of the data under the null hypothesis (H<sub>0</sub>).

<sup>c</sup> Calculated by random effects frequentist meta-analysis.

<sup>d</sup> BF<sub>rf</sub> is the ratio of the probability of the data under the random-effects model over the probability of the data under the fixed-effect model.

<sup>e</sup> Data are Hedges' g values.
meta-analysis found no evidence for or against publication bias in any of the meta-analyses (eTable 4 in Supplement 1).

**Discussion**

To our knowledge, this is the first bayesian meta-analysis pooling the published data on the association between PDA and BPD-PH as diagnosed by echocardiogram. Bayesian meta-analysis showed that the evidence for an association with BPD-PH was extreme for surgically treated PDA and for the continuous variable duration of PDA exposure. In addition, the evidence was moderate for hsPDA and strong for the dichotomous variable prolonged exposure to PDA. Taken together, the present data support the hypothesis that sustained patency of a hemodynamically significant ductal shunt may be a key contributor to the pathogenesis of BPD-PH.10,11,54

For some clinicians, PDA has acquired the status of a benign event, with treatment resulting in more complications than benefits. In the absence of a consensus on how, when, and which infants to treat for PDA, a growing number of neonatologists are adopting a less interventional approach to management of PDA.55-57 As a result, an increasing number of preterm infants are and will be potentially exposed to a prolonged ductal shunt.58,59 As pointed out by El-Khuffash et al,60 it is unlikely that a true hsPDA with chronic left-to-right shunting does not play a role in pulmonary...

**Figure 2. Bayesian Model Averaged Meta-Analysis of the Association of Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension (BPD-PH) With Patent Ductus Arteriosus (PDA)**

<table>
<thead>
<tr>
<th>Study, y</th>
<th>Exposed/Total</th>
<th>Log OR (95% CrI)</th>
<th>Decreased risk</th>
<th>Increased risk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BPD-PH, Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BPD-PH, No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim et al,40 2012</td>
<td>23/25</td>
<td>-0.71 (-2.56 to 1.14)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trittman et al,52 2014</td>
<td>22/36</td>
<td>-0.36 (-1.15 to 0.43)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ra et al,47 2013</td>
<td>13/18</td>
<td>-0.20 (-1.38 to 0.97)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Check et al,33 2013</td>
<td>22/39</td>
<td>0.12 (-0.63 to 0.86)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bianca et al,50 2018</td>
<td>7/8</td>
<td>0.19 (-2.02 to 2.40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weismann et al,54 2017</td>
<td>17/44</td>
<td>0.28 (-0.44 to 1.01)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mourani et al,55 2017</td>
<td>17/39</td>
<td>0.46 (-0.23 to 1.15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vyasa-Read et al,56 2017</td>
<td>43/59</td>
<td>0.73 (0.13 to 1.33)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gentle et al,10 2023</td>
<td>36/82</td>
<td>1.08 (0.48 to 1.68)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bruno et al,31 2015</td>
<td>32/37</td>
<td>1.19 (0.21 to 2.16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed effects</td>
<td></td>
<td>0.45 (0.19 to 0.71)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Random effects</td>
<td></td>
<td>0.37 (-0.04 to 0.73)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Averaged</td>
<td></td>
<td>0.41 (0.03 to 0.72)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study, y</th>
<th>Exposed/Total</th>
<th>Log OR (95% CrI)</th>
<th>Decreased risk</th>
<th>Increased risk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BPD-PH, Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BPD-PH, No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sheth et al,49 2020</td>
<td>31/59</td>
<td>0.16 (-0.43 to 0.76)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vyasa-Read et al,52 2017</td>
<td>18/59</td>
<td>1.20 (0.58 to 1.82)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gentle et al,10 2023</td>
<td>32/82</td>
<td>1.39 (0.73 to 2.05)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed effects</td>
<td></td>
<td>0.84 (0.49 to 1.19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Random effects</td>
<td></td>
<td>0.71 (-0.13 to 1.48)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Averaged</td>
<td></td>
<td>0.74 (-0.10 to 1.41)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A. Graph shows data for any PDA. B. Graph shows data for hemodynamically significant PDA. The size of the diamonds denotes the 95% credible interval (CrI). OR indicates odds ratio.
vascular remodeling during the first few weeks of life. Accordingly, the highest evidence for an association between PDA and BPD-PH came from the group of analyses that considered the duration of ductal shunting as a continuous or categorical variable (Figure 4).

It could also be speculated that surgical ligation of PDA is a surrogate for prolonged exposure to hsPDA. This speculation is based on the fact that ligation is usually reserved for those infants in whom conservative or pharmacological treatment of PDA has failed or is contraindicated.61 In a recent retrospective study62 of a cohort of 2418 very-low-birth-weight infants who underwent invasive PDA closure, the median age at the time of the procedure was approximately 30 days. However, it cannot be overlooked that in several neonatology centers, surgical ligation of PDA has been the preferred first-line treatment for small preterm infants.61 Only 2 of the studies62,69 included in the meta-analysis provided information on the timing of invasive PDA closure. Interestingly, Lagatta et al42 observed that the median time at which infants underwent PDA ligation was approximately 2 weeks longer in the BPD-PH group than in the group without BPD-PH. In contrast, Sheth et al49 did not find any association of early (<28 days) vs late surgical closure of PDA with development of BPD-PH.

The association of PDA with BPD is complex, with a number of seemingly contradictory findings.63 Preclinical studies64 in baboons showed that exposure for 2 weeks to a moderate-to-large PDA led to a decrease in alveolar surface area and accentuated the arrest in alveolar development that characterizes BPD. However, smooth muscle abundances around terminal bronchioles and their neighboring pulmonary arteries were not affected by exposure to ductal shunt.64 Several recent single-center observational studies62,64-69 have shown that infants with small PDA shunts do not appear to be at increased risk for developing BPD. Instead, an association of PDA with BPD is apparent only when moderate-to-large shunts persist beyond 7 to 14 days.63,65-70 Interestingly, the duration of exposure to mechanical ventilation appears to play an important role in the interaction between PDA and BPD. Thus, Clyman et al63,71 showed that infants exposed to mechanical ventilation for more than 10 days developed the most severe forms of BPD, particularly when they had concurrent exposure to a moderate-to-large PDA for at least 7 to 14 days.

A reliable assessment of the impact of PDA on BPD risk requires randomized clinical trials (RCTs) in which enrollment is limited to infants with the highest risk of abnormal outcomes and in whom

---

**Figure 3. Bayesian Model-Averaged Meta-Analysis of the Association of Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension (BPD-PH) With Surgically Ligated or Catheter Occluded Patent Ductus Arteriosus (PDA)**

<table>
<thead>
<tr>
<th>Study, y</th>
<th>PDA-exposed/total</th>
<th>BPD-PH, Yes</th>
<th>BPD-PH, No</th>
<th>Log OR (95% CrI)</th>
<th>Decreased risk</th>
<th>Increased risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kawai et al,38 2022</td>
<td>0/9</td>
<td>19/122</td>
<td>-1.28 (-4.16 to 1.61)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Lagatta et al,42 2018</td>
<td>69/370</td>
<td>303/1307</td>
<td>-0.27 (-0.57 to 0.02)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Slaughter et al,50 2011</td>
<td>5/29</td>
<td>10/49</td>
<td>-0.21 (-1.40 to 0.98)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Weismann et al,54 2017</td>
<td>11/44</td>
<td>21/115</td>
<td>0.40 (-0.43 to 1.23)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Check et al,31 2013</td>
<td>13/39</td>
<td>23/99</td>
<td>0.50 (-0.31 to 1.31)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Mourani et al,45 2015</td>
<td>9/39</td>
<td>35/238</td>
<td>0.55 (-0.27 to 1.38)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Sheth et al,49 2020</td>
<td>17/59</td>
<td>25/161</td>
<td>0.79 (0.08 to 1.50)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>An et al,25 2010</td>
<td>14/29</td>
<td>22/87</td>
<td>1.01 (0.14 to 1.89)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Ali et al,31 2013</td>
<td>2/17</td>
<td>2/57</td>
<td>1.30 (-0.74 to 3.34)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Bruno et al,31 2015</td>
<td>20/37</td>
<td>64/266</td>
<td>1.31 (0.61 to 2.02)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Wang et al,53 2022</td>
<td>26/59</td>
<td>34/209</td>
<td>1.40 (0.77 to 2.33)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Cartón-Sánchez,32 2016</td>
<td>11/22</td>
<td>12/62</td>
<td>1.43 (0.38 to 2.47)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Aswani et al,28 2016</td>
<td>10/19</td>
<td>42/211</td>
<td>1.50 (0.54 to 2.46)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Kanaan et al,37 2018</td>
<td>24/163</td>
<td>37/1177</td>
<td>1.67 (1.13 to 2.21)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Salomon et al,48 2022</td>
<td>4/15</td>
<td>1/19</td>
<td>1.88 (-0.44 to 4.19)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Nawaytou et al,11 2023</td>
<td>6/22</td>
<td>12/234</td>
<td>1.94 (0.83 to 3.04)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
</tr>
<tr>
<td>Fixed effects</td>
<td>0.58 (0.40 to 0.76)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Random effects</td>
<td>0.84 (0.44 to 1.23)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Averaged</td>
<td>0.84 (0.44 to 1.23)</td>
<td>![ ]</td>
<td>![ ]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The size of the diamonds denotes the 95% credible interval (CrI). OR indicates odds ratio.
spontaneous ductal closure is less likely. This would ensure that ductal shunt exposure is of sufficient magnitude and duration. Conversely, the control group should achieve a high rate of ductal closure. In the last few years, several RCTs have compared early (within the first 24-72 hours after birth) pharmacologic treatment of PDA vs placebo or vs an expectant attitude toward PDA. However, all these RCTs focused exclusively on the incidence of BPD, without consideration of the impact of PDA on pulmonary vascular development or risk of PH. Four trials found no effect of early PDA treatment on the incidence of BPD, and another even reported a higher incidence of moderate-to-severe BPD in the group receiving treatment. Nevertheless, it should be noted that spontaneous ductal closure by the end of the first week occurred in as many as 20% to 50% of infants in the control group of these RCTs. In addition, ibuprofen, the drug used in most of the RCTs, closed the PDA in only 50% to 70% of the infants. Therefore, there was substantial overlap between the intervention and control groups in terms of PDA exposure.

The absence of association between a potential risk factor and BPD is not an indication that it cannot have an association with BPD-PH. The current definition of BPD, which is based on the need for supplemental oxygen and/or respiratory support at 36 weeks postmenstrual age, is an umbrella term that cannot discriminate the contribution of airway, parenchymal lung, interstitium, or pulmonary vascular disease to the respiratory difficulty. In recent years, considerable effort has been devoted to the characterization of various BPD phenotypes. Among the potential phenotypic subgroups, the so-called vascular phenotype is characterized by the associated presence of PH. A pathological condition such as PDA may have a specific effect on the development of the vascular phenotype of BPD without an effect on the overall incidence of BPD. An example of this was found when we recently analyzed the association between hypertensive disorders of pregnancy and BPD. Although hypertensive disorders of pregnancy were not associated with moderate-to-severe BPD, they were associated with an increased risk of developing BPD-PH.

Figure 4. Bayesian Model-Averaged Meta-Analysis of the Association Between Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension (BPD-PH) and Prolonged Exposure to Patent Ductus Arteriosus (PDA)

A Prolonged PDA

<table>
<thead>
<tr>
<th>Study, y</th>
<th>Exposed/Total</th>
<th>Log OR (95% CrI)</th>
<th>Decreased risk</th>
<th>Increased risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slaughter et al,50 2011</td>
<td>17/29</td>
<td>23/49</td>
<td>0.47 (-0.46 to 1.40)</td>
<td></td>
</tr>
<tr>
<td>Weismann et al,54 2017</td>
<td>5/44</td>
<td>6/115</td>
<td>0.85 (-0.40 to 2.09)</td>
<td></td>
</tr>
<tr>
<td>Wang et al,51 2022</td>
<td>45/59</td>
<td>61/209</td>
<td>2.05 (1.38 to 2.72)</td>
<td></td>
</tr>
<tr>
<td>Gentle et al,10 2023</td>
<td>33/114</td>
<td>5/157</td>
<td>2.52 (1.54 to 3.50)</td>
<td></td>
</tr>
<tr>
<td>Nawaytou et al,11 2023</td>
<td>13/22</td>
<td>9/234</td>
<td>3.59 (2.51 to 4.67)</td>
<td></td>
</tr>
<tr>
<td>Philip et al,46 2021</td>
<td>17/20</td>
<td>3/46</td>
<td>4.40 (2.70 to 6.09)</td>
<td></td>
</tr>
<tr>
<td>Fixed effects</td>
<td></td>
<td></td>
<td>1.98 (1.58 to 2.38)</td>
<td></td>
</tr>
<tr>
<td>Random effects</td>
<td></td>
<td></td>
<td>1.67 (0.19 to 2.78)</td>
<td></td>
</tr>
<tr>
<td>Averaged</td>
<td></td>
<td></td>
<td>1.67 (0.23 to 2.80)</td>
<td></td>
</tr>
</tbody>
</table>

B Time of exposure to PDA

<table>
<thead>
<tr>
<th>Study, y</th>
<th>Sample size</th>
<th>Hedges g (95% CrI)</th>
<th>Lower in BPD-PH group</th>
<th>Higher in BPD-PH group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gentle et al,10 2023</td>
<td>82</td>
<td>138</td>
<td>0.94 (0.66-1.23)</td>
<td></td>
</tr>
<tr>
<td>Lagatta et al,42 2018</td>
<td>79</td>
<td>559</td>
<td>1.13 (0.89-1.37)</td>
<td></td>
</tr>
<tr>
<td>Nawaytou et al,11 2023</td>
<td>22</td>
<td>234</td>
<td>1.30 (0.85-1.75)</td>
<td></td>
</tr>
<tr>
<td>Fixed effects</td>
<td></td>
<td></td>
<td>1.08 (0.90-1.25)</td>
<td></td>
</tr>
<tr>
<td>Random effects</td>
<td></td>
<td></td>
<td>1.01 (0.34-1.46)</td>
<td></td>
</tr>
<tr>
<td>Averaged</td>
<td></td>
<td></td>
<td>1.06 (0.74-1.30)</td>
<td></td>
</tr>
</tbody>
</table>

A, Graph shows PDA as categorical variable. B, Graph shows PDA as continuous variable. The sizes of the diamonds denote the 95% credible interval (CrI). OR indicates odds ratio.
Limitations
The main limitation of the included studies, and therefore of our meta-analysis, is the difficulty in assessing both exposure (PDA) and outcome (BPD-PH). This may account for the high heterogeneity we found in some analyses. With regard to exposure, a majority of the included studies were retrospective and did not report the time of diagnosis or treatment of PDA or the rate of response to treatment. In addition, the diagnostic criteria for hsPDA or the time limit defining prolonged exposure to PDA are the subject of ongoing and far from settled debate. It is important to note that the hemodynamic meaning of PDA is affected by factors such as the transductal diameter, the balance between pulmonary and systemic vascular resistance, and the compensatory capacity of the immature myocardium. These factors may vary over time and with clinical evolution, but this complexity is not reflected in the dichotomization of the data required by meta-analysis.

Regarding the outcome, cardiac catheterization is the criterion standard test for the diagnosis of PH, but the procedure is generally reserved for a limited group of infants because of its invasiveness. Echocardiography, on the other hand, has the advantage of being noninvasive and allows for serial clinical evaluation. Echocardiography screening for PH is currently recommended for infants with moderate-to-severe BPD (ie, those requiring supplemental oxygen or respiratory support at 36 weeks postmenstrual age). However, there is a lack of consensus on the echocardiography diagnostic criteria for PH in this group of infants. The echocardiography-derived measurements of PH can be classified into 3 categories: (1) indirect assessment of elevated right ventricle afterload and estimation of pulmonary hemodynamics (eg, increased tricuspid regurgitant jet velocity or flattening of the interventricular septum); (2) evaluation of measures of right and left ventricle performance; and (3) appraisal of the predominant direction of flow and degree of extrapulmonary shunts across the PDA and foramen ovale.

The studies included in the present meta-analysis used different combinations of these echocardiographic measurements (see eTable 2 in Supplement 1). However, none of these individual metrics is free from criticism regarding accuracy in the diagnosis of PH and limited ability to differentiate between high flow, elevated pulmonary vascular resistance (PVR), pulmonary venous hypertension from left ventricular diastolic dysfunction, or pulmonary vein stenosis as contributors of PH.

The only study included in the meta-analysis that determined the presence of PH by cardiac catheterization was Philip et al. Although that study included a very selective group of infants, its findings are very relevant to differentiate the relative role of high flow vs high PVR in BPD-PH when a ductal shunt is present. They retrospectively analyzed a series of 100 infants with GA less than 27 weeks who underwent hemodynamic evaluation before transcatheter PDA closure. In 64 infants, they observed an elevated pulmonary arterial systolic pressure (defined as pulmonary-to-systemic ratio >0.5). However, only 20 of these 64 infants had an increase in PVR. In the remaining 44 infants, the elevated pulmonary arterial systolic pressure was secondary to increased pulmonary blood flow from the PDA. Interestingly, of the 20 infants with elevated PVR, 17 had been exposed to PDA for more than 8 weeks. These data suggest that prolonged exposure to PDA often leads to pulmonary vascular disease.

Conclusions
The findings summarized in this bayesian meta-analysis suggest that prolonged exposure to PDA may be associated with increased risk of pulmonary vascular disease in extremely preterm infants. This emphasizes the necessity of monitoring PH in high-risk preterm infants with prolonged exposure to PDA and incorporating the risk of developing PH into clinical decisions regarding definitive PDA closure by surgery or catheter occlusion. In addition, PH should be included as important outcome in clinical trials of PDA management.


Table of Contents


SUPPLEMENT 1.
eAppendix. Supplemental Methods
eFigure 1. Flow Diagram of the Systematic Search
eFigure 2. Bayesian Model Averaged Meta-Analysis on the Association Between Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension and (A) Medically Treated Patent Ductus Arteriosus (PDA), and (B) Medically or Surgically Treated PDA
eTable 1. Characteristics of the Included Studies
eTable 2. Criteria for Echocardiographic Assessment of Pulmonary Hypertension in the Different Studies
eTable 3. Data on Heterogeneity of the Bayesian Model-Averaged Meta-Analysis (BMA)
eTable 4. Analysis of Publication Bias by Robust Bayesian Meta-Analysis (RoBMA)
eTable 5. Adjusted Effect Sizes
eReferences

SUPPLEMENT 2.
Data Sharing Statement